Published in Antiviral Res on September 07, 2008
Efficient reverse genetics generation of infectious junin viruses differing in glycoprotein processing. J Virol (2009) 1.29
Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains. J Virol (2010) 1.09
Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants. PLoS Negl Trop Dis (2009) 0.91
Efficient rescue of recombinant Lassa virus reveals the influence of S segment noncoding regions on virus replication and virulence. J Virol (2011) 0.90
Architecture and regulation of negative-strand viral enzymatic machinery. RNA Biol (2012) 0.90
Reverse Genetics Approaches to Control Arenavirus. Methods Mol Biol (2016) 0.75
Reporter-Expressing, Replicating-Competent Recombinant Arenaviruses. Viruses (2016) 0.75
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell (1997) 17.78
The mammalian unfolded protein response. Annu Rev Biochem (2005) 16.31
Amplification, expression, and packaging of foreign gene by influenza virus. Cell (1989) 11.21
Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J (1989) 10.84
ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell (2000) 9.13
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther (2005) 6.04
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 5.73
Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med (2006) 5.42
Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell (2006) 5.10
Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature (1990) 5.02
Mechanism of intrinsic transcription termination and antitermination. Science (1999) 4.55
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Viral late domains. J Virol (2002) 4.51
Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell (2003) 4.25
The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology (2006) 3.46
The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci U S A (2001) 3.43
Mechanisms of enveloped RNA virus budding. Trends Cell Biol (2002) 3.36
The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci U S A (2003) 3.34
Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J Virol (2003) 2.87
NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol (2000) 2.74
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Genetic basis of viral persistence: single amino acid change in the viral glycoprotein affects ability of lymphocytic choriomeningitis virus to persist in adult mice. J Exp Med (1990) 2.59
Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med (1990) 2.57
Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J Virol (2003) 2.57
Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. Arch Biochem Biophys (2002) 2.57
Human cytomegalovirus infection activates and regulates the unfolded protein response. J Virol (2005) 2.56
New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res (2007) 2.47
Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response. J Virol (2002) 2.41
Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc Natl Acad Sci U S A (1999) 2.37
The SREBP pathway--insights from Insigs and insects. Nat Rev Mol Cell Biol (2003) 2.35
Human infection with arenaviruses in the Americas. Curr Top Microbiol Immunol (2002) 2.32
Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr Top Microbiol Immunol (2002) 2.32
Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem (1998) 2.28
Transcription and RNA replication of tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. J Virol (2001) 2.08
Cellular factors required for Lassa virus budding. J Virol (2006) 2.02
Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J Virol (2002) 1.97
Lymphocytic choriomeningitis virus--an old enemy up to new tricks. N Engl J Med (2006) 1.94
Treatment of Argentine hemorrhagic fever. Antiviral Res (2007) 1.93
Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell (1993) 1.90
West Nile virus infection activates the unfolded protein response, leading to CHOP induction and apoptosis. J Virol (2007) 1.86
Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep (2003) 1.85
RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. J Virol (2001) 1.84
Biochemical and immunological evidence that the 11 kDa zinc-binding protein of lymphocytic choriomeningitis virus is a structural component of the virus. Virus Res (1992) 1.82
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci U S A (2006) 1.79
Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology (2003) 1.76
Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology (2003) 1.75
The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J Virol (2004) 1.74
Effective vaccine for lassa fever. J Virol (2000) 1.74
Lymphocytic choriomeningitis virus. A neglected pathogen of man. Arch Pathol Lab Med (1992) 1.71
Replicon system for Lassa virus. J Virol (2004) 1.69
Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol (2003) 1.69
Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis (1998) 1.69
Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J Virol (2002) 1.68
Hematopoietic receptor complexes. Annu Rev Biochem (1996) 1.67
Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein-protein or protein-DNA interactions. Angew Chem Int Ed Engl (2003) 1.66
Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol (2001) 1.66
A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? J Gen Virol (2002) 1.60
Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J Virol (1985) 1.60
Rescue of the prototypic Arenavirus LCMV entirely from plasmid. Virology (2006) 1.58
Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol (2004) 1.58
Metabolism and antiviral activity of ribavirin. Virus Res (2005) 1.57
Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis. Am J Ophthalmol (2000) 1.57
Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis (2001) 1.57
Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2003) 1.56
Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am J Obstet Gynecol (2002) 1.50
Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J Virol (2003) 1.50
Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis (1997) 1.48
Toward automated synthesis of oligosaccharides and glycoproteins. Science (2001) 1.46
Lymphocytic choriomeningitis virus and immunology. Curr Top Microbiol Immunol (2002) 1.45
Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis (2001) 1.45
Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK. J Virol (2003) 1.45
Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J Virol (2002) 1.44
Reverse genetics of mononegavirales. Curr Top Microbiol Immunol (2004) 1.44
Endoplasmic reticulum stress is a determinant of retrovirus-induced spongiform neurodegeneration. J Virol (2003) 1.43
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J Biol Chem (2001) 1.42
Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci U S A (2003) 1.41
Complementarity in the supramolecular design of arenaviruses and retroviruses revealed by electron cryomicroscopy and image analysis. J Virol (2005) 1.40
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res (2005) 1.38
Site 1 protease is required for proteolytic processing of the glycoproteins of the South American hemorrhagic fever viruses Junin, Machupo, and Guanarito. J Virol (2008) 1.37
Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J Virol (2005) 1.36
Arenaviruses: genomic RNAs, transcription, and replication. Curr Top Microbiol Immunol (2002) 1.35
Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res (2008) 1.31
Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem (2008) 1.29
Arenavirus Z-glycoprotein association requires Z myristoylation but not functional RING or late domains. J Virol (2007) 1.27
The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis (2001) 1.27
Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother (1988) 1.26
Junin virus vaccines. Curr Top Microbiol Immunol (2002) 1.23
Perturbation of differentiated functions during viral infection in vivo. II. Viral reassortants map growth hormone defect to the S RNA of the lymphocytic choriomeningitis virus genome. Virology (1985) 1.22
Receptor structure, binding, and cell entry of arenaviruses. Curr Top Microbiol Immunol (2002) 1.21
Carbohydrate Mimetics: A New Strategy for Tackling the Problem of Carbohydrate-Mediated Biological Recognition. Angew Chem Int Ed Engl (1999) 1.20
Strategies for the Design of Drugs Targeting RNA and RNA-Protein Complexes. Angew Chem Int Ed Engl (2000) 1.19